Welcome to our dedicated page for PARK HA BIOLOGICAL TECHNOLOGY SEC filings (Ticker: BYAH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Park Ha Biological Technology Co., Ltd.'s SEC filings document the regulatory record of a Cayman Islands foreign private issuer with operating subsidiaries that sell Park Ha skincare and cosmetic products in China. Current reports on Form 6-K cover Nasdaq listing compliance, board changes, shareholder voting matters and amendments to its memorandum and articles.
The company's filings also describe its capital structure, including Class A ordinary shares, Class B ordinary shares with higher voting rights, warrants issued in public offerings, securities purchase agreements, placement agency arrangements and Form F-1 registration statement disclosures. These records connect financing activity and share-capital matters to BYAH's public-company governance and reporting obligations.
Park Ha Biological Technology Co., Ltd. plans a 1-for-50 reverse stock split of its Class A and Class B ordinary shares. The change has already been approved by shareholders and the board, and is expected to become effective on February 20, 2026, with trading beginning on a split-adjusted basis that day.
Immediately before the reverse split, the company has 104,768,362 ordinary shares issued and outstanding, reflecting its recent follow-on offering and related warrant exercises. After the reverse split, the share count is expected to be adjusted to 2,095,368 ordinary shares. Fractional shares will not be issued; any fractional amounts will be rounded up to the nearest whole share. The company does not anticipate other material changes to the terms of its securities in connection with this action.
Park Ha Biological Technology Co., Ltd. plans a 1-for-50 reverse stock split effective February 20, 2026, with trading to begin on a split-adjusted basis that day, subject to satisfying Nasdaq Operations notice requirements.
To align with this change, the company amended its Memorandum of Association to reduce authorized share capital from USD 3,000,000.00 divided into 150,000,000,000 ordinary shares of par value US$0.00002 each (120,000,000,000 Class A and 30,000,000,000 Class B) to 3,000,000,000 ordinary shares of par value US$0.001 each (2,400,000,000 Class A and 600,000,000 Class B), using the same 1-for-50 ratio as the issued and outstanding shares.
Shareholders approved the reverse split at an extraordinary meeting on December 26, 2026, and the Board of Directors set the exact ratio on January 29, 2026.
Park Ha Biological Technology Co., Ltd. completed a best-efforts follow-on public offering of 21,875,000 units at US$0.112 per unit, raising approximately US$2.45 million in gross proceeds before fees and expenses. Each unit includes one Class A ordinary share and one warrant.
Each warrant has a US$0.112 exercise price, is exercisable immediately, and expires one year after the January 28, 2026 issue date. The warrants allow either standard cash exercise or an alternative cashless exercise that can deliver up to nine Class A ordinary shares per warrant. The company engaged D. Boral Capital LLC as sole placement agent, paying a 7.0% cash fee on aggregate gross proceeds and reimbursing specified expenses. Net proceeds are intended for expanding directly operated stores in China, with allocation across markets based on prevailing conditions.
Park Ha Biological Technology Co., Ltd. is offering 21,875,000 Units, each with one Class A Ordinary Share and one Warrant, and registering 196,875,000 Class A Ordinary Shares issuable upon Warrant exercise. The public offering price is $0.112 per Unit, for a maximum gross proceed of $2,450,000 on a best-efforts basis.
Each Warrant initially allows purchase of one Class A Ordinary Share at $0.112 for one year, but also includes a zero exercise price option under which holders may receive nine Class A Ordinary Shares per Warrant for no additional consideration, up to 196,875,000 shares in total. The company expects no meaningful cash proceeds from Warrant exercises and plans to use estimated net offering proceeds of about $2.142 million mainly to expand directly operated stores.
Class A Ordinary Shares trade on Nasdaq as “BYAH.” The company operates skincare product development and franchised stores in China through PRC subsidiaries, with revenues primarily from product sales and franchise fees, and highlights extensive regulatory, structural, and PRC-related legal and cash-transfer risks, as well as dual-class voting control concentrated with its founder.
Park Ha Biological Technology Co., Ltd. filed Amendment No. 3 to its Form F-1 registration statement to update certain exhibits and restate the exhibit index, while leaving the previously filed prospectus unchanged.
The filing describes Cayman Islands–style indemnification for directors and officers, subject to limits under Cayman law and U.S. Securities Act public policy, and confirms standard SEC undertakings related to post-effective amendments and offering liability.
It also reviews recent unregistered securities activity, including 5,000,000 Ordinary Shares issued on October 11, 2022 at incorporation, a June 29, 2024 forward split, a December 2024 IPO of 1,200,000 Ordinary Shares at $4.00 per share plus a 174,403-share over-allotment, and share issuances of 3,000,000 and 4,500,000 Ordinary Shares under the 2025 and Amended and Restated 2025 Share Incentive Plans, contributing to 33,874,403 Ordinary Shares issued and outstanding out of 2,500,000,000 authorized as of the prospectus date.